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reported higher CD4+ cell counts in women, while
Farzadegan et al. [7] found very similar counts for
both genders. Since the present ﬁndings do not
apply to individuals presenting with category C
conditions or CD4+ cell counts < 200 ⁄lL, it would
seem that there is no need to establish gender-
dependent thresholds in this population to guide
initiation of treatment. However, it might be
worth reconsidering the threshold for asympto-
matic women presenting with CD4+ counts
> 200 ⁄lL so that they receive highly active anti-
retroviral therapy at an earlier stage in the disease.
There are several limitations to these ﬁndings.
First, self-reported data are subject to recall bias or
to other reporting errors. Second, as in all retro-
spective studies, some data may be missing or
incorrectly entered. Third, this study population,
considered to represent patients seeking care for
the ﬁrst time, may also include a small number of
people who had sought care elsewhere and, in the
absence of preceding AIDS-deﬁning illnesses,
were not treated with anti-retroviral therapies.
Nevertheless, this retrospective analysis found
that new female entrants to HIV care had higher
CD4+ cell counts and lower VLs, and were less
likely to be seropositive for hepatitis B infection.
Whether women in Cleveland seek HIV testing
earlier, or whether early markers of HIV disease
differ between the genders, remains to be deter-
mined.
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ABSTRACT
This study evaluated the role of linezolid in the
treatment of patients suffering from pneumococ-
cal meningitis. Treatment included ceftriaxone
(4000 mg every 24 h), linezolid (600 mg every
12 h) and dexamethasone (8 mg every 6 h).
Linezolid was withdrawn if a penicillin-suscept-
ible isolate of Streptococcus pneumoniae was iden-
tiﬁed. Of 16 patients studied, seven were infected
with penicillin-non-susceptible isolates of S. pneu-
moniae, two died, and three reported sequelae. No
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toxicity was reported. It was concluded that
linezolid can be used for the treatment of pneu-
mococcal meningitis, as an alternative to vanco-
mycin or rifampicin, in regimens including a
third-generation cephalosporin.
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Spread of penicillin-resistant strains of Streptococcus
pneumoniae has complicated the empirical treatment
of bacterial meningitis because of the absence of
antimicrobial agents that are as effective and safe as
penicillin and third-generation cephalosporins
[1–3]. Linezolid is an oxazolidinone with excellent
activity against multidrug-resistant Gram-positive
bacteria, including multidrug-resistant strains of
staphylococci and enterococci causing central
nervous system (CNS) infections. Although linezo-
lid is a candidate for the treatment of pneumococ-
cal meningitis because of its activity against
penicillin-susceptible and penicillin-resistant iso-
lates of S. pneumoniae, and its penetration into
cerebrospinal ﬂuid (CSF) regardless of meningeal
inﬂammation, its efﬁcacy for treating such infec-
tions has not been evaluated previously [4–8]. The
present study aimed to assess the safety and efﬁ-
cacy of combined ceftriaxone and linezolid therapy
in patients with severe meningitis caused by
penicillin-non-susceptible isolates ofS. pneumoniae.
Consecutive comatose adult patients referred to
our tertiary care centre who were diagnosed with
S. pneumoniae meningitis by CSF pleocytosis
(> 10 cells ⁄lL) and positive pneumococcal CSF
antigens, and who were at risk for infection by
penicillin-non-susceptible isolates [9], were en-
rolled following written informed consent from
their legal representative. Inclusion criteria were:
(i) an age of > 18 years; (ii) a diagnosis of
meningitis, as established by clinical and laborat-
ory ﬁndings; and (iii) CSF or blood cultures
positive for S. pneumoniae. Exclusion criteria were:
(i) co-infection with human immunodeﬁciency
virus; and (ii) antimicrobial treatment within the
48 h preceding admission.
Blood and CSF samples were obtained for cyto-
biochemical and microbiological studies, inclu-
ding the detection of pneumococcal antigen,
before the start of antibiotic treatment. Once the
diagnosis of pneumococcal meningitis was estab-
lished, empirical treatment with ceftriaxone
(4000 mg intravenously every 24 h) and linezolid
(600 mg intravenously every 12 h) was adminis-
tered [10]; linezolid was withdrawn if a penicillin-
susceptible strain of S. pneumoniae was cultured.
Linezolid and ceftriaxone, or cefriaxone only,
were administered for 20 days following admis-
sion. The rationale behind the choice of a longer
period of therapy with respect to current guide-
lines was the compromised status of the study
population. Dexamethasone (8 mg intravenously
every 6 h) was administered 15–20 min before the
administration of antibiotics for the ﬁrst 4 days
[11]. A control lumbar puncture was performed
after treatment for 48 h. Laboratory data (i.e., full
blood count, blood urea, creatinine and alanine-
aminotransferase levels) were assessed at admis-
sion, after 48 h, and during the course of therapy.
Blood and CSF samples were inoculated into
BACTEC Plus Aerobic ⁄ F bottles (Becton-Dickin-
son, Franklin Lakes, NJ, USA) and incubated in
the BACTEC 9240 system (Becton-Dickinson).
Positive cultures were subcultured on sheep
blood agar and chocolate agar and incubated in
a CO2 5% v ⁄v atmosphere. Isolate identiﬁcation
was conﬁrmed by conventional microbiological
methods, and antimicrobial susceptibilities were
determined using Etests (AB Biodisk, Solna,
Sweden) [12]. The outcome measure was based
on the Glasgow Outcome Scale at 8 weeks [13].
Nineteen patients with pneumococcal menin-
gitis were enrolled initially, but three of these
patients were excluded subsequently because of
negative cultures. Data for the remaining 16
patients are summarised in Table 1. Main risks
for carriage of penicillin-resistant S. pneumoniae
were antibacterial treatment within the preceding
30 days and chronic underlying disease. Ten
patients (four infected with penicillin-susceptible
isolates) had at least two factors associated with
an adverse outcome [14]. Six patients required
mechanical ventilation for 2–8 days within 48 h of
the appearance of symptoms. S. pneumoniae iso-
lates from nine patients were penicillin-suscept-
ible. Intermediately-resistant or resistant isolates
were obtained from seven patients. Six penicillin-
non-susceptible isolates were also resistant to
erythromycin (MIC 4–256 mg ⁄L) and one
was resistant to ceftriaxone (MIC 2 mg ⁄L). All
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isolates were susceptible to vancomycin
(MIC < 0.5 mg ⁄L), rifampicin (MIC < 1 mg ⁄L)
and linezolid (MIC < 0.5 mg ⁄L) (Table 2). Fol-
lowing treatment for 48 h, all cases showed a
reduction in cell counts and protein, and an
increase in the glucose level in CSF samples, as
well as an absence of bacterial growth from blood
and CSF samples. Patients infected with penicil-
lin-susceptible isolates of S. pneumoniae received
ﬁve to seven doses of linezolid before suscepti-
bility data became available and the drug was
withdrawn. A complete course of therapy was
administered to all surviving patients without
haematological, nephro- or hepato-toxicity.
Overall, two patients died (patients 7 and 16;
Table 2) and three (patients 2, 6 and 15) reported
sequelae. The two deaths occurred 6 and 9 days
after enrolment with patients aged > 70 years who
were afﬂicted with chronic debilitating diseases.
Of seven patients infected with penicillin-non-
susceptible isolates, one died, one reported severe
disability, one had mild disability (hearing loss),
and four recovered fully.
The mortality rate for pneumococcal meningitis
dropped during the 1980s when third-generation
cephalosporins were introduced for the empirical
treatment of community-acquired meningitis. No
reduction was observed when combined regimens
including a cephalosporin and vancomycin or
rifampicin were introduced [15]. Vancomycin or
rifampicin are currently recommended in regi-
mens including third-generation cephalosporins
for pneumococcal meningitis. However, their use
should be revisited for several reasons, including:
(i) the non-therapeutic concentration of vancomy-
cin obtained within CSF when dexamethasone is
administered; (ii) the emergence of rifampicin-
resistant isolates of S. pneumoniae during rifampi-
cin monotherapy, which cannot be excluded when
a cephalosporin-resistant isolate is involved; and
(iii) the occurrence of rifampicin-induced chole-
static hepatitis, which is life-threatening in patients
with liver cirrhosis [16–18].
As dexamethasone has been shown to improve
the outcome following bacterial meningitis, it is
suggested that administration of drugs such as
linezolid, which are capable of good penetration
through the blood–brain barrier regardless of the
use of steroids, is of great value in patients with
pneumococcal mentingitis [11]. In the present
study, ceftriaxone and linezolid showed good
efﬁcacy without toxicity. Indeed, cytobiochemical
parameters improved after therapy for 48 h, no
microbiological failures were reported when
















1 60 F Liver cirrhosis, otitis No No No 5 1320.0 2900
2 64 F Liver cirrhosis, pneumonia Yes No No 21 84.5 3000
3 61 M Liver cirrhosis, pneumonia Yes No No 25 500.8 700
4 27 M Splenectomy No No No 5 596.2 700
5 32 F CSF ﬁstula, minor thalassaemia No No No 1 1433.2 1800
6 30 F Splenectomy, major thalassaemia, otitis Yes Yes Yes 20 355.6 3200
7 79 M Diabetes Yes No Yes 6 362.5 650
8 58 M Otitis No No No 60 157.0 20000
9 60 M Otitis Yes Yes Yes 5 450.2 650
10 49 F CSF ﬁstula No No No 29 562.0 540
11 57 F Diabetes Yes Yes Yes 12 306.0 1500
12 30 M None Yes Yes Yes 1 405.5 18000
13 43 F Otitis Yes No No 6 321.0 3000
14 41 F Otitis Yes Yes No 1 560.3 200
15 50 M Otitis Yes No No 22 154.3 5200
16 70 M Chronic renal failure, pneumonia Yes Yes Yes 15 104.2 70
Table 2. Susceptibility of Streptococcus pneumoniae isolates,













1 0.125 0.016 20 – 5
2 0.5 0.016 20 – 5c
3 0.5 0.016 20 – 5
4 1 0.125 20 – 5
5 2 0.250 20 – 5
6 2 2 20 – 3
7 2 0.250 6 – 1
8 0.016 0.008 2 18 5
9 0.016 0.016 3 17 5
10 0.008 0.016 3 18 5
11 0.016 0.016 2 18 5
12 0.016 0.016 2 18 5
13 0.016 0.008 3 17 5
14 0.032 0.016 3 17 5
15 0.032 0.016 3 17 4
16 0.016 0.008 2 7 1
GOS, Glasgow Outcome Scale score.
aCeftriaxone 4000 mg every 24 h and linezolid 600 mg every 12 h.
bCeftriaxone 4000 mg every 24 h.
cMild hearing impairment.
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either penicillin- or ceftriaxone-resistant isolates
were involved, and the fatality rate was lower
than that observed in other series of patients with
severe pneumococcal meningitis.
Since several factors, including combined ther-
apy, may inﬂuence the outcome of pneumococcal
bacteraemia and meningitis, the recommendation
for use of linezolid is based on its safety proﬁle, its
good in-vitro and in-vivo efﬁcacy, and its excel-
lent penetration through the blood–brain barrier
[19]. Further studies should be performed to
establish the precise value of linezolid in improv-
ing the prognosis for patients following pneumo-
coccal meningitis.
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